Takeda’s CFO departs forcing company to act
pharmafile | March 14, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Takeda, biotech, drugs, pharma, pharmaceutical
Takeda has announced that its Chief Financial Officer, James Kehoe, has decided to move on from the company to take up the same position at Walgreens Boots Alliance. Replacing him in the position will be Costa Saroukos, current CFO of Takeda’s Europe and Canada Business Unit (EUCAN).
Kehoe will step down from his role as CFO on 31 March and resign from the Board of Directors, officially leaving Takeda on 31 May. Saroukos will begin his new role as CFO for the company on 1 April.
Saroukos has plenty of experience of the pharmaceutical industry to draw upon, having already worked in varying roles for MSD, known as Merck in North America, over the course of 13 years and having worked at Allergan as CFO in a regional capacity for China and Japan.
He has worked at Takeda for over three years, after joining the company as Interim President and CFO for Europe and Canada.
“We are excited for Costa to take on this new role as CFO,” said Christophe Weber, President and CEO of Takeda. “For the past three years, he has been overseeing the EUCAN Business Unit’s finance team and has played an instrumental role in the enhancement of Takeda’s presence in Europe and Canada. He also was extremely involved in global programs especially the Global Opex Initiative. We expect a seamless transition and are confident that his leadership will contribute to Takeda’s mid- and long-term growth.”
For Kehoe, it marks a shift in focus – from pharmaceuticals to a healthcare group. Regarding his two-year tenure in the position, Takeda’s press release read: “Mr. Kehoe has strengthened the Global Finance function to drive sustainable long-term future growth and performance. Through his leadership, he has elevated Takeda’s operational business performance while spearheading the Global Opex Initiative, which will continue to improve profitability.”
Related Content
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
